SCHEMBL21747253

SCHEMBL21747253

Cc1ccc(C(=O)CCC2OCCCO2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.54
KMT2A Q03164 6/20 0.50
CTNNB1 P35222 3/20 0.50
WNT3A P56704 3/20 0.50
GSK3B P49841 1/20 0.44
POLB P06746 2/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.39
PAX8 Q06710 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7284408 0.93 NPC1 (0.54) NPC1RAB9ASMN1; SMN2LMNAGAA
SCHEMBL3215720 0.84 RAB9A (0.53) NPC1RAB9ASMN1; SMN2KMT2ACTNNB1
SCHEMBL21747244 0.84 KMT2A (0.50) NPC1RAB9ASMN1; SMN2KMT2AGSK3B
SCHEMBL3390902 0.84 ALDH1A1 (0.49) SMN1; SMN2LMNAKMT2AGSK3BCES2
SCHEMBL2207700 0.83 KDM4E (0.51) SMN1; SMN2LMNAGAAKMT2ACTNNB1
SCHEMBL1670496 0.83 MAPT (0.53) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL3303126 0.80 GSK3B (0.49) NPC1RAB9AGSK3BPOLBALDH1A1
SCHEMBL3392114 0.77 KMT2A (0.51) SMN1; SMN2LMNAKMT2AGSK3BPOLB
SCHEMBL7210582 0.77 NPC1 (0.56) NPC1RAB9ASMN1; SMN2KMT2ACTNNB1
SCHEMBL7287642 0.77 KMT2A (0.53) NPC1RAB9ASMN1; SMN2KMT2AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 NPC1 1271/4885RAB9A 2900/4885SMN1; SMN2 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.